A Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis

A Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Safety, Efficacy, and Tolerability Study of Two Doses of Epinastine Nasal Spray (0.05% and 0.1%) vs. Placebo in Subjects With Seasonal Allergic Rhinitis

The purpose of this trial is to determine the safety, efficacy and tolerability of two doses of the study drug compared to placebo for the treatment of subjects with seasonal allergic rhinitis.

Inclusion Criteria:

• A documented history of seasonal allergic rhinitis to mountain cedar pollen

Exclusion Criteria:

• Significant medical condition
• Cardiovascular abnormality
• Have a significant physical obstruction in the nose
• Started or had a change in immunotherapy within the 30 days prior to

screening

• Have nasal ulceration(s) or any active nasal bleeding
• Require use of allergy medications during the study
• Require use of asthma medications other than as needed albuterol